Cardiac Magnetic Resonance Predicting Outcomes Among Patients at Risk for Cardiac AL Amyloidosis

• Published in: Frontiers in cardiovascular medicine 2021-06, Vol.8, p.626414-626414
• Main Authors: Agha, Ali M., Palaskas, Nicolas, Patel, Amit R., DeCara, Jeanne, Parwani, Purvi, Iliescu, Cezar, Durand, Jean B., Kim, Peter, Hassan, Saamir, Gladish, Gregory, Lee, Hans C., Kaufman, Gregory P., Lopez-Mattei, Juan C.
• Format: Article
• Language: English
• Subjects: cardiac magnet resonance; cardio-oncology; Cardiovascular Medicine; CMR; diagnosis; prognosis
• ISSN: 2297-055X; 2297-055X
• DOI: 10.3389/fcvm.2021.626414

Introduction: Patients with systemic AL amyloidosis (AL) should be evaluated for cardiac amyloidosis (CA), as prognosis is strongly related to cardiac involvement. We assessed the characteristics of patients referred to cardiac magnetic resonance (CMR) with suspected CA from a cancer center and determine predictors of mortality/heart failure hospitalizations (HFH). Methods: Forty-four consecutive patients referred for CMR with suspected CA were retrospectively included. Variables collected included cardiac biomarkers, in addition to echocardiographic and CMR variables. Survival analyses were performed to determine which variables were more predictive of mortality and HFH. Results: Of the 44 patients included, 55% were females. 73% of patients were diagnosed with CA by CMR; 56% of them had an established diagnosis of AL. Patients with CA by CMR had higher native T1, higher extracellular volume (ECV) fraction, higher T2, less negative GLS by Echo, and higher troponin I and B-type natriuretic peptide (BNP). Kaplan-Meier survival analysis revealed that the following were predictive of mortality: an ECV ≥ 0.50 ( p = 0.0098), CMR LVEF < 50% ( p = 0.0010), T2/ECV ≤ 100 ( p = 0.0001), and troponin I > 0.03 ( p = 0.0025). In a stepwise conditional Cox logistic regression model, the only variable predictive of a composite of mortality and HFH was ECV (HR: 1.17, 95% CI = 1.02–1.34 p = 0.030). Conclusion: ECV seems to be an important biomarker that could be a predictor of outcomes in cardiac AL amyloidosis. In combination, CMR and serum cardiac biomarkers might help to establish prognosis in patients with CA.